Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Y3M | ISIN: NO0010779341 | Ticker-Symbol: 9Y8
Frankfurt
06.06.25 | 15:29
0,160 Euro
+4,86 % +0,007
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOINVENT ASA Chart 1 Jahr
5-Tage-Chart
ONCOINVENT ASA 5-Tage-Chart

Aktuelle News zur ONCOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Oncoinvent ASA: Minutes from the annual general meeting 2025-
30.04.Oncoinvent Q1 2025 slides: promising cancer therapy data, solid cash position1
30.04.Oncoinvent ASA: Notice of Annual General Meeting-
ONCOINVENT Aktie jetzt für 0€ handeln
28.04.Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update178OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English...
► Artikel lesen
28.04.Oncoinvent ASA: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression3
28.04.Oncoinvent AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression223OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month...
► Artikel lesen
28.04.ONCOINVENT AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression3
28.04.Oncoinvent ASA: Financial calendar1
25.03.Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients1
05.03.Oncoinvent ASA: Mandatory notification of trade-
27.02.Oncoinvent ASA: Fourth Quarter 2024 Update and Results1
27.02.Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients1
26.02.Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference244Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference...
► Artikel lesen
20.02.Oncoinvent ASA: Invitation to Result Presentation Q4 2024392OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events: Thursday...
► Artikel lesen
19.02.Oncoinvent ASA to present at various conferences-
18.02.Oncoinvent ASA: Registration of new share capital-
06.02.Oncoinvent ASA: Last day of the subscription period in the subsequent offering1
04.02.Oncoinvent ASA: Grant of share options - mandatory notification of trade-
23.01.Oncoinvent ASA: Commencement of subscription period for subsequent offering2
22.01.Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering-
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1